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Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and liver cancer, is curable in most people. Injecting
drug use currently accounts for 80 % of new HCV infections with a known transmission route in the European Union
(EU). HCV has generally received little attention from the public or policymakers in the EU, with major gaps in
national-level strategies, action plans, guidelines and the evidence base. Specifically, people who inject drugs (PWID)
are often excluded from treatment owing to various patient, healthcare provider and health system factors.
All policymakers responsible for health services in EU countries should ensure that prevention, treatment, care and
support interventions addressing HCV in PWID are developed and implemented. According to current best practice,
PWID should have access to comprehensive, evidence-based multiprofessional harm reduction (especially opioid
substitution therapy and clean needles and syringes) and support/care services based in the community and modified
with community involvement to accommodate this hard-to-reach population. Other recommended components of
care include vaccination against hepatitis B and other infections; peer support interventions; HIV testing, prevention
and treatment; drug and alcohol services; psychological care as needed; and social support services. HCV testing
should be performed regularly in PWID to identify infected persons and engage them in care. HCV-infected PWID
should be considered for antiviral treatment (based on an individualised assessment and delivered within
multidisciplinary care/support programmes) both to cure infected individuals and prevent onward transmission.
Modelling data suggest that the HCV disease burden can only be cut substantially if antiviral treatment is scaled
up together with prevention programmes. Measures should be taken to reduce stigma and discrimination against
PWID at the provider and institutional levels.
In conclusion, strategic action at the policy level is urgently needed to increase access to HCV prevention, testing
and treatment among PWID, the group at highest risk of HCV infection. Such action has the potential to substantially
reduce the number of infected persons, along with the disease burden and related care costs.
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According to the World Health Organization (WHO),
14 million people in the European Region are chronically
infected with hepatitis C virus (HCV), a blood-borne in-
fection of the liver [1]. Another recent study has estimated
that there are 3.6 million people with viraemic HCV infec-
tions in the EU [2]. HCV is a leading cause of liver cirrho-
sis and liver cancer and around 70,500 infected people die
each year in the European Union as a result of these com-
plications [3]. Without action, the burden of HCV disease* Correspondence: j.f.dillon@dundee.ac.uk
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of the infected population, ongoing new infections and
low levels of treatment uptake [4–6]. For example, the
number of HCV-related cirrhosis cases in England is ex-
pected to increase by 50 % by 2030, while HCV-related
deaths will almost double [4].
Injecting drug use currently accounts for 80 % of new
HCV infections in the European Union with a known
transmission route [7]. Globally, two out of three people
who inject drugs (PWID) have HCV infection [8], with
rates in European Union countries varying between 14 %
and 84 % [9]. However, HCV remains a hidden epidemic.
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diagnosed (range: 24–76 %) [10]. HCV is transmitted
more easily than HIV and globally there are more than
three times as many PWID infected with HCV than with
HIV [8]. When formulating strategies to address the prob-
lem of HCV infection, especially if considering treatment
as prevention strategies, it is important to differentiate be-
tween individuals who are currently active drug injectors
and those who are former injectors. In addition, among
active injecting drug users, it is important to distinguish
between those who share injecting equipment and those
who do not. HCV is spread between PWID primarily by
the sharing of injection equipment and thus the vast
majority of new infections occurs in active injectors
who share.
The window of opportunity for HCV prevention is nar-
row, as infection is likely to occur soon after initiation of
injection drug use. The time to infection is shortest
among individuals with many contacts within their net-
work of drug users and among those who inject most
frequently [11]. Furthermore, the incidence of infection
is highest among individuals who do not utilise existing
harm reduction services such as opioid substitution
therapy (OST) and sterile needle and syringe programmes
(NSP). HCV in PWID is preventable and curable, and
therefore efforts to reduce the incidence and transmis-
sion of HCV infection must aim to increase access to
testing, risk reduction and treatment in this popula-
tion, with a strong focus on active injectors. Treatment
with antiviral medicines is as effective in PWID as in
non-drug users [12], and guidelines published by inter-
national and European organisations identify the pre-
vention and treatment of HCV among PWID as major
components of protecting the public from blood-borne
viruses [13–16].
The European Commission recognises PWID as a key
target group in its ongoing activities to address blood-
borne viruses, and in October 2015 it launched a three-
year Joint Action that engaged representatives of 18
Member States in efforts to intensify the response to HIV
and viral hepatitis among PWID [17] and followed this up
with a second Joint Action on these issues in 2016. How-
ever, considering the extent of the public health threat,
HCV has generally received little attention from the pub-
lic or policymakers in the European Union, with major
gaps in international and national-level strategies, action
plans, guidelines and in the evidence base more generally
[10, 18–20]. This paper discusses barriers to improving
HCV care for PWID and current best practices in HCV
prevention, diagnosis and treatment in PWID in the con-
text of recent data and relevant policy initiatives. It con-
cludes by making policy recommendations to address
unmet needs in PWID and thereby strengthen the re-
sponse to HCV in the European Union.Barriers to improving HCV care for PWID
A recent study of the EU countries found an overall
diagnosis rate for HCV infection of 33 % and a treat-
ment rate of 3.7 % [2]. Median treatment rates specific-
ally among diagnosed PWID have been estimated at
around 10–30 % [10, 21], but this masks wide variation
within and between countries and of course many PWID
are not even diagnosed. A study of seven sites in the UK
found that treatment rates among PWID varied from <5
to >25 per 1000 PWID [22]. Of course, many more
PWID are not even diagnosed. Access to prevention,
testing and treatment is even more limited in prisons
than in the community, despite high rates of HCV in the
prison population internationally [23, 24] as well as legal
and human rights obligations for governments to pro-
vide health care to prison inmates.
A fundamental dilemma is that PWID, in whom HCV
infection is most common and in whom treatment to
prevent onward transmission is particularly important,
are generally difficult to engage in formal healthcare ser-
vices. PWID are often wrongly excluded from treatment,
and uptake rates are low even where treatment is of-
fered. The main barriers to PWID accessing care for
HCV include [21, 25–28]:
 Patient-related factors, such as lack of awareness of
diagnosis or HCV status; limited knowledge or
negative perceptions of HCV and how it is treated;
low levels of health literacy; negative relations with
the healthcare system, including fear of or experience
of stigmatization; social, medical and psychiatric
co-morbidities; lack of insurance; low socioeconomic
status; homelessness or unstable housing; and factors
relating to migrant status or ethnic/cultural minority
status;
 Healthcare provider-related factors, such as limited
expertise in HCV care for PWID; misperceptions
that treatment is less effective or is associated with
high re-infection rates in PWID versus non-PWID
groups; and discrimination or stigmatization toward
PWID;
 System-related and institutional factors, such as
lack of infrastructure or treatment settings
adapted or conveniently located for PWID; lack of
coordination or collaboration among providers of
different services; lack of suitable training
programmes; high treatment fees; criminalisation
of PWID; and a lack of validated, shared,
systematic national data on the health and
economic impact of HCV to inform service
investment and planning.
Programmes for HCV treatment as prevention will
only work if high levels of coverage and adherence are
Fig. 1 Components of comprehensive hepatitis C virus (HCV) care
services to which people who inject drugs should have access
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HCV services need to be modified to effectively deliver
harm reduction interventions and antiviral treatment to
hard-to-reach populations. Survey data suggest that the
majority of PWID may be willing to receive treatment
for HCV if it is available to them [29]. However, whether
individuals undertake and adhere to treatment in practice
will depend on how they prioritise this option in relation
to various competing priorities and challenges [26]. Some
individuals may need particular encouragement, making
advocacy and peer support important features of efforts to
scale up treatment.
The question of whether further measures to incentiv-
ise PWID into care should be employed, and what form
these should take, has received little attention to date. In
conventional health services, patients with symptoms are
motivated to seek health care as a means of obtaining
relief from the symptoms. Similarly, patients are moti-
vated to participate in HCV testing programmes because
of their recognition that a diagnosis can lead to the
timely initiation of treatment, reducing the risk of com-
plications from the disease. In both cases, health-seeking
behaviour is rewarded. In the PWID population, these
mechanisms may be much less powerful. PWID often
have quite nihilistic views of the future [30, 31], and as
HCV is frequently asymptomatic, there are few drivers
for treatment-seeking behaviour. This is compounded
further if early treatment is perceived to principally benefit
society (in terms of prevention of transmission, as dis-
cussed below) rather than infected individuals. Such per-
ceptions may result from the asymptomatic nature of
early infection or a lack of knowledge or concern about
the long-term consequences of chronic HCV infection
among some PWID. Additionally, for treatment as pre-
vention strategies to work, the uptake of treatment needs
to be high, as a small number of individuals at key points
in networks could reinfect many people who have been
cured. Therefore, incentives or contingency management
programs should be considered. Assessed in a variety of
diseases and populations by the National Institute for
Health and Care Excellence in England and Wales and
found to be cost-effective and acceptable [32], these
should be considered a key component of motivating ac-
tive PWID populations into treatment.
Crucially, many countries lack national evidence-based
best practice programmes such as the one implemented
and evaluated in Scotland [33]. In 2006, the Scottish
Government launched its Hepatitis C Action Plan for the
purposes of improving services to prevent transmission of
HCV infection (particularly among PWID), identifying
those infected, and ensuring that those infected re-
ceive optimal treatment, care and support [33]. The
comprehensive plan was based on evidence from national
monitoring systems and models showing the potentialbenefit of scaling up therapy and the mounting cost of in-
action, and was informed by stakeholder consultations. It
was implemented by national and local multidisciplinary,
multi-agency networks, coordinated by Health Protection
Scotland and supported by substantial government invest-
ment. Achievements include an increase of approximately
50 % in the proportion of the infected population diag-
nosed (38 % to 55 %); a nearly three-fold increase in the
annual number of PWID initiating therapy, and a reversal
of the upward trend in the overall number of people living
with chronic HCV infection [33].Prevention, harm reduction and testing
There is currently no vaccine against HCV. However,
HCV infection among PWID can be greatly reduced
using a combination of prevention strategies [13, 34].
PWID should have access to comprehensive harm re-
duction and support/care services. These services should
also be based in the community, to facilitate access by
PWID and to aid service expansion. Guidelines by WHO
[13], the Joint United Nations Programme on HIV/AIDS
[35], the European Centre for Disease Prevention and
Control (ECDC)/European Monitoring Centre for Drugs
and Drug Addiction [14] and other experts [15, 16, 36] all
recommend packages of services that include the follow-
ing elements (Fig. 1).
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PWID should have easy access to harm reduction ser-
vices, two key components of which are OST and NSP
[13, 14, 35]. As well as reducing HCV risk behaviour
and transmission through injecting drug use, these in-
terventions can serve as a platform to promote HCV
care. While harm reduction services are often grouped
together, it is important to differentiate them and their
potential utility in efforts to combat HCV. NSP pro-
grammes by definition are focussed on those still inject-
ing and aim to make the act of injecting safer. Such
services greatly reduce the rate of transmission. There-
fore, it is logical to make this group the focus of
treatment-as-prevention strategies. OST services take
many forms across countries and regions depending on
local legal requirements and regulations; some are very
open to unstable and active injectors while others re-
quire PWID to modify their drug use to varying degrees
as a condition for initiating or continuing OST. The de-
sign of the OST service model has considerable impli-
cations for the efficacy of OST as a prevention tool for
HCV, with the only likely prevention benefit being seen
in the context of low-threshold early access leading to
reduced injecting frequency. The use of peer support
interventions within these services is recommended
[13, 14, 35]. Various models of peer support exist [37],
including those that promote education, engagement in
services, and treatment uptake and assessment [37–40].
HIV testing, prevention and care should be provided in
concert. Available data suggest that the prevalence of
HIV/HCV co-infection ranges widely across Europe,
depending on the prevalence of HIV [10]. Other recom-
mended components of care for PWID include: vaccin-
ation against other infections (e.g. hepatitis A and B,
tetanus), psychological care for selected cases, and so-
cial support services [13–16, 35, 41].
The 2013–2016 European Commission Action Plan on
Drugs charges Member States with ensuring that treat-
ment and outreach services incorporate greater access to
risk and harm reduction options to reduce the conse-
quences of drug use including transmission of blood-
borne viruses [42]. There are examples of good practice
underway in Europe [33, 43], but the unmet need is still
high [44, 45].
Testing
Many individuals with chronic HCV infection are diag-
nosed after being infected for many years and enter care
only when they develop clinical symptoms, despite hav-
ing been engaged by the healthcare system earlier [46].
Late diagnosis of HCV is associated with worse out-
comes [46] and with the risk of onward transmission.
Many opportunities for timely diagnosis of HCV infec-
tion are missed, especially in PWID populations. Activetesting of PWID who are current injectors is rarely
undertaken. It is argued that treatment of such patients
is too difficult, too expensive and the risk of re-infection
too high, although the developing evidence base clearly
shows that this is not the case. Additionally, the diagno-
sis of HCV may change behaviour in the short term or
identify patients who could be followed up for treatment
in the future before presenting with liver failure. Re-
cently, the European Association for the Study of the
Liver and the HIV in Europe initiative developed a new
consensus definition of late presentation for viral hepa-
titis [47]. This is an important performance indicator of
success for programmes aiming to improve the identifi-
cation and management of viral hepatitis.
HCV testing should be performed regularly in PWID
to identify infected persons and engage them in care and
treatment [13–16]. HCV antibody testing is recommended,
and if the result is positive, a more sensitive HCV RNA test
should be performed to determine whether or not there is
current infection [13, 16]. Targeted HCV testing linked to
treatment increases diagnosis rates and treatment uptake
[48] and is a cost-effective way to reduce the disease bur-
den [49]. New types of rapid and point-of-care HCV tests
(e.g. dried blood spot tests) can help to increase the num-
ber of tested individuals, especially in hard-to-reach groups
[13, 50]. However, according to a 2013 survey, only six of
44 countries in the European Region provided hepatitis B
and C virus testing to PWID at no charge [20].
Antiviral treatment: individual benefit and transmission
prevention
HCV antiviral treatment aims to cure, or eradicate, HCV
infection in individuals, thereby preventing its complica-
tions and death [15]. HCV treatments are assessed ac-
cording to the sustained virological response rate (SVR),
defined as the proportion of patients with undetectable
HCV RNA measured after 12 or 24 weeks according to
defined methods. Patients who achieve an SVR remain
free of the virus in 99 % of cases and hence are considered
cured [15, 51]. An SVR has been associated with signifi-
cantly reduced risks of 10-year all-cause mortality, and
liver-related mortality or transplantation, among HCV-
infected individuals with advanced hepatic fibrosis [52].
The introduction of direct-acting antiviral (DAA) ther-
apies in recent years has revolutionised the treatment of
HCV. Previously, pegylated interferon/ribavirin (peg-IFN/
RBV) regimens were only moderately effective (depending
on the HCV genotype), required IFN injections and vari-
able treatment durations up to 48 or even 72 weeks, and
were associated with significant toxicities. New all-oral
IFN-free DAA regimens, given for 8–24 weeks, are much
more effective (achieving SVR rates of ≥90 % in clinical
trials), and are generally well tolerated [13, 15, 53]. It can
be extrapolated that the much higher SVRs achieved will
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mortality seen with interferon-based regimens.
Currently, treatment priority is based on fibrosis stage,
risk of progression to more advanced disease, presence
of extrahepatic manifestations of infection and cirrhosis.
It should also take into account the risk of transmission
[15]. European and international guidelines recommend
that all patients with chronic HCV — including PWID —
should be considered for antiviral treatment based on an
individualised assessment [13–16, 35]. According to a
systematic review of studies, the effectiveness of peg-
IFN/RBV treatment among PWID who are eligible and
committed to starting HCV treatment (including active
injectors) is similar to that in non-drug users, with high
levels of adherence, low rates of treatment discontinu-
ation, and a low rate of reinfection among PWID [12].
These findings support current treatment recommen-
dations and refute misperceptions about poor effective-
ness and high rates of re-infection in PWID that can
lead to their exclusion from treatment. Indeed, PWID
are among the groups that should be prioritised for treat-
ment, regardless of fibrosis stage or extra-hepatic manifes-
tations, in view of their risk of transmitting HCV [15].
Patients who are co-infected with HCV and HIV should
also be prioritised for HCV treatment [15]. Importantly,
HCV treatment for PWID should be delivered within
multidisciplinary care/support programmes that include
harm reduction and support services [13–16, 35], includ-
ing measures to limit alcohol intake and to address obes-
ity, smoking and drug usage.
Curing HCV infection not only benefits infected indi-
viduals, but also has the potential to prevent onward
viral transmission and hence to reduce the disease bur-
den at the population level [13]. The impact of treat-
ment on HCV prevalence depends on its effectiveness
and on the levels of treatment uptake. Modelling studies
in various countries consistently suggest that current
levels of treatment using conventional peg-IFN/RBV reg-
imens are unlikely to significantly reduce or even stabilise
the disease burden over the next 10 to 15 years [4–6, 54].
According to models, the HCV disease burden can only
be cut substantially if antiviral treatment is scaled up to-
gether with prevention programmes [22, 54–60]. For ex-
ample, using dynamic modelling, researchers in the
United Kingdom projected that a 50 % reduction in the
prevalence of chronic HCV in PWID (from a baseline of
20 %, 40 % or 60 %) could be achieved within 10 years by
combining OST, NSP and antiviral treatment. A halving of
the prevalence was made more achievable (i.e. fewer treat-
ments were needed) if DAAs were used instead of peg-
IFN/RBV, and also if harm reduction were scaled up [55].
Further modelling, based on real-world data on treatment
rates and outcomes from 538 PWID in seven centres in
the United Kingdom, suggested that the introduction ofDAA therapies combined with the scaling up of treatment
to rates already achieved in some centres – to 26 per 1000
PWID – could allow all seven sites to achieve at least a
15 % absolute reduction in HCV prevalence after 10 years,
with prevalence more than halved in three sites [22]. In
Scotland, doubling treatment uptake and prioritising
PWID was projected to reduce incident infection to negli-
gible levels (<50 cases per year) by 2025 and to stabilise
rates of severe liver morbidity by 2028 [61]. Targeting
those with moderate/advanced fibrosis would stabilise se-
vere liver morbidity five years earlier, but would be signifi-
cantly less effective in reducing new infections. In Sweden,
modelling suggests that doubling the number of DAA
treatments overall would bring about 65–70 % reductions
in both the incidence of hepatocellular cancer and liver-
related deaths by 2030 [59]. Targeting only patients with
advanced fibrosis would only stabilise the incidence of
serious complications with minimal impact on the total
number of HCV infections. Internationally, other analyses
suggest that a 90 % reduction in total HCV infections
and/or disease burden within 15 years is feasible in most
countries studied, provided there is upscaling of testing,
harm reduction and efficacious treatment [5, 57].
Antiviral treatment among PWID, in combination with
harm reduction services, is therefore a critical component
of primary prevention of HCV. Despite implementation
challenges, treatment uptake rates of 20–22 % have
already been reported in dedicated services linking OST
and community hepatitis care [22, 62–64]. Furthermore,
experience from Scotland shows that a scale-up of anti-
viral therapy can be achieved without compromising SVR
rates, including among PWIDs [65].
The cost of DAA treatments is a barrier to their wide
usage in HCV management strategies in most European
Union countries. However, PWID were not widely treated
even during the previous era of lower cost therapies,
underlining the point that particular barriers such as dis-
crimination exist for this group. Economic models indi-
cate that HCV treatment using DAAs is cost-effective
owing to a reduction in the costs of HCV-related compli-
cations [66–69]. Few studies have assessed the cost-
effectiveness of antiviral treatment specifically for PWID
(Table 1). Modelling data from Australia and the United
Kingdom suggest that treating active or former PWID
with peg-IFN/RBV at mild stages of HCV is cost-effective
compared with no antiviral treatment, resulting in incre-
mental cost-effectiveness ratios (ICER, measured as cost
per quality adjusted life-years [QALY]) below standard
local thresholds for cost-effectiveness [70, 71]. The
Australian study and the UK study both took into ac-
count the costs of disease progression, together with
deleterious aspects such as reinfection, but only one
also took into account the prevention effects of treat-
ment on transmission [70].
Table 1 Studies modelling the cost-effectiveness of antiviral therapy for hepatitis C virus infection in people who inject drugs (PWID)
Reference Country/setting Design Intervention and population Cost impact
PegIFN/RBV therapy
Martin et al. 2012 [70] United Kingdom Dynamic disease progression and
transmission model
pegIFN/RBV at mild stage vs no treatment
(best supportive care) in:
ICER for treating current PWID vs no treatment,
according to baseline chronic HCV prevalence:
Probablistic cost-utility analysis Current PWID 20 % prevalence: ICER treat PWID vs no treatment = £521/QALY
Direct medical costs (2010 prices) Non/ex PWID 40 % prevalence: ICER vs no treatment = £2539/QALY
N = 1000 individuals 60 % prevalence: ICER = £7675a/QALY
Treatment of non/ex-PWID dominant at 60 %
prevalence; ICER £6803/QALY vs no treatment
Visconti et al. 2013 [71] Australia Markov decision-analytic model pegIFN/RBV at mild (F0/1) stage vs
no treatment (best supportive care) in:
Current PWID: $AUS 7941/QALY
Direct medical costs (2011 prices) Current PWID Former PWID: $AUS 5808/QALY
Former PWID Non-injectors: $AUS 3985/QALY
Non-injectors Treatment at mild stage dominated treatment at later
stages for all cohorts
N = 1000 individuals
DAA therapy
Bennett et al. 2015 [58] United Kingdom Dynamic model of disease progression,
transmission and treatment
Uptake increased to 250 per
1000 PWID of:
2015–2027
Current treatment Current treatment: £23.4 million saved (£5.4 after discounting)
New DAA (SVR90%) SVR90%: £36.3 million saved (£8.4 million after discounting)
Lifetime complication rates, costs of
complications
N = 4240 individuals
Hellard et al. 2015 [72] Australia Closed compartmental model of
disease progression and treatment
IFN-free DAA at Late treatment vs no treatment: $AUS5078
Early stage (from F0) Early treatment vs late treatment: $AUS17,090
Fixed rate of re-infection Late-stage (from F2/3)
Direct healthcare costs (2014 prices) N = 1000 individuals
Scott et al. 2016 [73] Australia Open compartmental model of
progression, transmission and treatment
DAA treatment scale up necessary
to achieve WHO goals of 65 %
reduction in HCV-related deaths
and 80 % reduction in HCV
incidence by 2030 via two scenarios
if DAA treatment for IDU-acquired
HCV prioritised to: Patients with
advanced liver disease (F ≥ 3) or
Current PWID
Prioritising advanced liver disease: Mortality target required 5662
(95 % CI 5202–6901) courses/year (30/1000 IDU-acquired infections)
Prioritising PWID:
Incidence and mortality targets achieved with 4725
(95 % CI 3278–8420) courses per year (59/1000 PWID)
Additional 5564 (1959–6917) treatments/year (30/1000 IDU-acquired
infections) required for 5 years for patients with advanced liver disease
to avoid excess HCV-related deaths
ICER: $AUS25,121 ($AUS11,062–$AUS39,036)/QALY
DAA direct acting agents, F0–3 METAVIR score, ICER incremental cost-effectiveness ratio, pegIFN/RBV peglyated interferon/ribavirin, QALY quality-adjusted life-years, SVR sustained virological response
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evaluated the impact and cost-effectiveness of interferon-
free DAAs in PWID. One study, based on UK data and in-
tegrating disease progression and transmission according
to a previous model [55], projected that an increase in
uptake of conventional treatment with a 58 % SVR
from 10 per 1000 PWID to 250 per 1000 PWID (among
a modelled population of 4240 PWID with HCV preva-
lence of 25 %) would result in cost savings of £5.4 million
between 2015 and 2027 after discounting at 3.5 % per
annum [58]. Using newer treatments with a 90 % SVR was
projected to increase the amount saved to £36.3 million,
or £8.4 million after discounting [58].
In Australia, Hellard et al. modelled the expected
healthcare costs and QALYs among newly HCV-infected
PWID according to three scenarios: no treatment; ‘early’
treatment after initial infection; or ‘late’ treatment prior
to developing compensated cirrhosis [72]. Compared
with no treatment, early treatment and late treatment were
associated with ICERs of AUS $10,272/QALY (95 % CI
$5689–13,690) and AUS $5078/QALY (95 % confidence
interval $2847–5295), respectively. Both of these values are
well below the unofficial Australian willingness to pay
threshold of AUS $50,000/QALY. Early treatment was the
most effective option in terms of QALYs gained, while late
treatment was associated with a lower ICER because of a
lower likelihood of re-infection in patients treated later in
the course of infection due to the cessation of injection
drug use. These researchers acknowledged that their ana-
lysis may have underestimated the cost-effectiveness of
treatment for two reasons: it did not take into account any
benefits from reduced infection transmission, and the costs
of care for cirrhosis and liver cancer were based on mini-
mum requirements [72].
Most recently, these authors have used a model that
includes HCV transmission as well as disease progres-
sion and treatment, to estimate the treatment scale up
and cost-effectiveness of reaching WHO targets of an
80 % reduction in incidence and 65 % reduction in
HCV-related deaths by 2030, specifically among PWID
[73]. According to this analysis, achieving the mortality
target would require treatment to be scaled up to 30/1000
injecting drug use-acquired infections per year among
patients with advanced liver disease, while the incidence
target required 59/1000 PWID to be treated each year.
Prioritising treatment at this level only to PWID would
achieve the mortality target with fewer treatment
courses in total, but at the expense of a clinically un-
acceptable number of deaths among individuals with
advanced disease. Hence, additional treatments (at the
aforementioned rate, 30/1000/year) were required for
patients with advanced liver disease for the first five years.
Achieving both targets in this way was associated with
an ICER of AUS $25 121 (AUS$11 062–AUS$39 036)per QALY gained, below the unofficial cost-effectiveness
threshold [73].
Conclusion and recommendations
The hepatitis C pandemic is a pressing public health
threat. Strategic action at the policy level is urgently
needed to increase access to HCV prevention, testing
and treatment among PWID, the group at highest risk of
HCV infection. Such action has the potential to substan-
tially reduce the number of infected persons, along with
the disease burden.
The World Health Organization has called for a global
movement to create generalized access to HCV treat-
ment [13], as have civil society organisations and other
stakeholders [74]. They have further called for national
and European strategies on HCV that include specific
measures for PWID [28, 75, 76]. In 2014, the 67th
World Health Assembly approved a resolution urging
Member States to develop and implement coordinated
multi-sectoral national strategies for preventing, diagnosing
and treating viral hepatitis based on the local epidemio-
logical context [77]. The first-ever WHO Global Health
Sector Strategy on Viral Hepatitis (2016–2021) was
adopted by the 69th World Health Assembly on 28 May
2016 [78]. Aiming to contribute to the United Nations
Sustainable Development Goals [79] and to eliminate
viral hepatitis as a public health threat by 2030, the
strategy highlights the opportunities available through
investing in an essential, priority set of core interventions
that include comprehensive integrated harm reduction
services for PWID, linked with treatment [78]. This global
strategy is complemented by a draft WHO European
Region action plan for consideration by the Regional
Committee in September 2016 [80]. Additionally, in the
2014–2016 EU Action Plan on HIV and Co-infections,
the European Union has committed to work with Member
States, neighbouring countries, civil society and the ECDC
to implement risk and harm reduction measures for
PWID and their partners for the prevention and treatment
of HIV, co-infections and drug dependency in the com-
munity and prisons [81].
All policymakers responsible for health services in
European Union countries should ensure that:
 National HCV action plans and strategies that include
measures specifically to address HCV in PWID are
developed and implemented across Europe;
 Evidence-based, comprehensive, multi-professional,
community-led harm reduction and care/support
programmes are provided and linked to HCV
testing and treatment in the public and prison
health systems;
 PWID have equitable access to effective HCV
treatment, in line with published guidelines;
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discrimination against PWID at the provider and
institutional levels;
 HCV awareness and prevention campaigns are
undertaken for healthcare providers (doctors, nurses
and allied health professionals) and the PWID
community; and
 The PWID community is involved in HCV service
planning and implementation, with consideration
given to peer support and PWID ‘champions’
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